

## CONVENIENCE TRANSLATION – ONLY GERMAN VERSION IS BINDING



**Biofrontera AG**  
**Leverkusen**

- ISIN: DE000A4BGGM7 / WKN: A4BGGM -

### **Invitation to the Annual General Meeting**

We hereby invite our shareholders to the Annual General Meeting to be held on **June 10, 2026**, at 10:00 a.m. at the Wasserturm Hotel Cologne, Kaygasse 2, 50676 Cologne, Germany.

#### **I. Agenda**

- 1. Presentation of the adopted annual financial statements and the approved consolidated financial statements, the combined management report and group management report, the Executive Board's explanatory report on the disclosures pursuant to Sections 289a and 315a of the German Commercial Code (AktG), and the Supervisory Board's report for the fiscal year ended December 31, 2025**

The Supervisory Board has approved the annual financial statements and the consolidated financial statements prepared by the Management Board in accordance with Sections 171 and 172 of the German Stock Corporation Act (AktG). The annual financial statements are thus adopted in accordance with Section 172 AktG. A resolution by the Annual General Meeting to adopt the annual financial statements or to approve the consolidated financial statements pursuant to Section 173 of the German Stock Corporation Act (AktG) is therefore not required. The remaining aforementioned documents also need only be made available to the Annual General Meeting pursuant to Section 176(1), sentence 1 of the German Stock Corporation Act (AktG). The documents will be available on the Company's website at

<https://www.biofrontera.com/de/investoren/hauptversammlung>

. No resolution is required regarding agenda item 1.

- 2. Resolutions on the discharge of the members of the Management Board for the fiscal year 2025**

The Management Board and Supervisory Board propose that discharge be granted to the members of the Management Board in office during the 2025 fiscal year.

This resolution applies only to Ms. Pilar de la Huerta Martínez, who was the sole member of the Executive Board in the 2025 fiscal year.

### **3. Resolution on the discharge of the members of the Supervisory Board for the fiscal year 2025**

The Executive Board and the Supervisory Board propose that discharge be granted to the members of the Supervisory Board serving in the 2025 fiscal year.

In the 2025 fiscal year, the Supervisory Board consisted of:

- a) Alexander Link, Chairman
- b) Dr. Helge Lubenow, Vice Chair
- c) Dr. Heikki Lanckriet
- d) Karlheinz Schmelig
- e) Hansjoerg Plaggemars
- f) Tobias Reich

### **4. Resolution on the appointment of the auditor for the annual and consolidated financial statements for the fiscal year 2026, as well as the auditor for any review of the condensed interim financial statements and interim management report**

The Supervisory Board proposes—based on the recommendation of its Audit Committee—that the following resolution be adopted:

*Nexia GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Georg-Glock-Straße 4, 40474 Düsseldorf, is appointed as the auditor of the annual and consolidated financial statements for the fiscal year 2026, as well as the auditor for any review of the condensed interim financial statements and interim management report as of June 30, 2026, in accordance with Section 115(5) of the Securities Trading Act (WpHG).*

The Audit Committee has declared that its recommendation is free from undue influence by third parties and that no clause restricting its selection options within the meaning of Article 16(6) of the Audit Regulation (EU) No. 537/2014 has been imposed on it.

### **5. Resolution on New Elections to the Supervisory Board**

Pursuant to Sections 95, 96(1), 101(1) of the German Stock Corporation Act (“AktG”) in conjunction with Section 12(1) of the Articles of Association, and consists of six members who are elected by the Annual General Meeting for the period until the conclusion of the Annual General Meeting that decides on their discharge for the fourth fiscal year following the start of their term of office, provided that the Annual General Meeting does not specify a shorter term

of office at the time of election. The term of office of the current six members of the Supervisory Board ends upon the conclusion of the Annual General Meeting that decides on their discharge for the fiscal year ending on December 31, 2025, i.e., upon the conclusion of the Annual General Meeting on June 10, 2026. The Supervisory Board is therefore to be re-elected with the same composition.

The Supervisory Board proposes that the following resolutions be adopted:

- 5.1 Mr. Alexander Link, a member of the Management Board of Deutsche Balaton AG, residing in Frankfurt am Main, is to be elected to the Supervisory Board effective as of the conclusion of the Annual General Meeting on June 10, 2026, and for the period until the conclusion of the Annual General Meeting that decides on his discharge for the fiscal year ending December 31, 2030.**

Disclosures pursuant to Section 125(1), Sentence 5 of the German Stock Corporation Act (AktG):

Memberships in other statutory supervisory boards as well as in comparable domestic and foreign supervisory bodies of commercial enterprises:

- Carus AG, Heidelberg, Germany, Member of the Supervisory Board
- SPARTA Invest AG, Heidelberg, Germany, Chairman of the Supervisory Board
- SPK Süddeutsche Privatkapital AG, Heidelberg, Germany, Chairman of the Supervisory Board
- bioXXmed AG, Düsseldorf, Germany, Vice Chairman of the Supervisory Board
- Epigenomics AG, Heidelberg, Germany, Vice Chairman of the Supervisory Board
- MISTRAL Media AG, Frankfurt am Main, Germany, Vice Chairman of the Supervisory Board
- DIO Deutsche Immobilien Opportunitäten AG, Frankfurt am Main, Germany, Member of the Supervisory Board
- 4basebio PLC, Cambridge, United Kingdom, Non-Executive Director
- Nestmedic S.A., Warsaw, Poland, Member of the Supervisory Board

Deutsche Balaton AG, whose CEO is Alexander Link, is part of a group of companies headed by Wilhelm K. T. Zours, to whom 62.23% of the voting rights in Biofrontera AG are attributed according to the most recent voting rights notification. 31.38% of the voting rights in Biofrontera AG are held directly by Deutsche Balaton AG. Consequently, there is a business relationship between Alexander Link and a shareholder with a significant stake in the company.

Furthermore, in the opinion of the company's Supervisory Board, Alexander Link has no personal, or business relationship with the company or its group companies, the company's governing bodies, or a shareholder holding a significant stake in the company that would require disclosure under C.13 of the German Corporate Governance Code.

**5.2 Dr. Helge Lubenow, independent management consultant and managing director of Heidelberg Epignostix GmbH, residing in Bad Nauheim, is elected to the Supervisory Board effective as of the conclusion of the Annual General Meeting on June 10, 2026, and for the period until the conclusion of the Annual General Meeting that decides on her discharge for the fiscal year ending December 31, 2030.**

Information pursuant to Section 125(1), Sentence 5 of the German Stock Corporation Act (AktG):

Memberships in other statutory supervisory boards as well as in comparable domestic and foreign supervisory bodies of commercial enterprises:

- Epigenomics AG, Berlin, Germany, Chair of the Supervisory Board
- Human Gesellschaft für Biochemika und Diagnostika mbH, Wiesbaden, Germany, Advisory Board Member
- Neracare GmbH, Munich, Germany, Member of the Supervisory Board
- Avelo AG, Schlieren, Switzerland, Member of the Board of Directors

The group of companies led by Wilhelm K. T. Zours, to whom 62.23% of the voting rights in Biofrontera AG are attributed according to the most recent voting rights notification, holds a 29.14% stake in Epigenomics AG, whose Supervisory Board Chair is Dr. Helge Lubenow. Consequently, there is a business relationship between Dr. Helge Lubenow and a shareholder with a significant stake in the company.

Furthermore, in the opinion of the company's Supervisory Board, Dr. Helge Lubenow has no personal or business relationship with the company or its group companies, the company's governing bodies, or a shareholder holding a significant stake in the company that would require disclosure under C.13 of the German Corporate Governance Code.

**5.3 Dr. Heikki Lanckriet, member of the Executive Board of 4basebio PLC, Cambridge, UK, residing in Cambridge, United Kingdom, is elected to the Supervisory Board effective as of the conclusion of the Annual General Meeting on June 10, 2026, and for the period until the conclusion of the Annual General Meeting that decides on his discharge for the fiscal year ending December 31, 2030.**

Disclosures pursuant to Section 125(1), Sentence 5 of the German Stock Corporation Act (AktG):

Memberships in other statutory supervisory boards as well as in comparable domestic and foreign supervisory bodies of commercial enterprises:

- Neophore Ltd, Cambridge, United Kingdom, Non-Executive Director

- I2i capital Ltd, Cambridge, United Kingdom, Member of the Board of Directors
- Kither Biotech S.R.L., Turin, Italy, Non-Executive Director
- Leucid Bio, London, United Kingdom, Non-Executive Director
- Neomatrix S.R.L., Rome, Italy, Non-Executive Director
- Biofrontera Inc., Woburn, Massachusetts, United States of America, Non-Executive Director

The group of companies led by Wilhelm K. T. Zours, to whom 62.23% of the voting rights in Biofrontera AG are attributed according to the most recent voting rights notification, holds a 32.95% stake in 4basebio PLC, of which Dr. Heikki Lanckriet is a member of the Board of Directors. Consequently, there is a business relationship between Dr. Heikki Lanckriet and a shareholder with a significant stake in the company.

Furthermore, in the opinion of the Company's Supervisory Board, Dr. Heikki Lanckriet has no personal or business relationship with the Company or its group companies, the Company's governing bodies, or a shareholder holding a significant stake in the Company that would require disclosure under C.13 of the German Corporate Governance Code.

**5.4 Mr. Karlheinz Schmelig, Managing Director, Creathor Venture Management GmbH, Bad Homburg, residing in Bensheim, is elected to the Supervisory Board effective as of the conclusion of the Annual General Meeting on June 10, 2026, and for the period until the end of the Annual General Meeting that decides on his discharge for the fiscal year ending December 31, 2030.**

Information pursuant to Section 125 (1) Sentence 5 of the German Stock Corporation Act (AktG):

Mr. Karlheinz Schmelig is currently not a member of any other statutory supervisory boards or comparable domestic or foreign supervisory bodies of commercial enterprises.

In the opinion of the Company's Supervisory Board, Mr. Karlheinz Schmelig has no personal or business relationship with the Company or its group companies, the Company's governing bodies, or a shareholder holding a significant interest in the Company that would require disclosure under C.13 of the German Corporate Governance Code.

**5.5 Mr. Hansjoerg Plaggemars, independent management consultant and member of the Executive Board of Delphi Unternehmensberatung AG, Stuttgart, residing in Stuttgart, is elected to the Supervisory Board effective as of the conclusion of the Annual General Meeting on June 10, 2026, and for the period until the end of the Annual General Meeting that decides on his discharge for the fiscal year ending December 31, 2030.**

Disclosures pursuant to Section 125(1), Sentence 5 of the German Stock Corporation Act (AktG):

Memberships in other statutory supervisory boards as well as in comparable domestic and foreign supervisory bodies of commercial enterprises:

- Patronus Resources Ltd., Australia, Non-Executive Director
- Theta Gold Mines Ltd., Australia, Non-Executive Director
- 4basebio PLC, Cambridge, United Kingdom, Non-Executive Director
- Altech Batteries LTD, Australia, Non-Executive Director
- Geopacific Resources Ltd, Australia, Non-Executive Director

Delphi Unternehmensberatung AG, whose CEO is Hansjoerg Plaggemars, is part of a group of companies under Wilhelm K. T. Zours, to whom 62.23% of the voting rights in Biofrontera AG are attributed according to the most recent voting rights notification. 19.61% of the voting rights in Biofrontera AG are directly held by Delphi Unternehmensberatung AG. Consequently, there is a business relationship between Hansjoerg Plaggemars and a shareholder with a significant stake in the company.

Furthermore, in the opinion of the company's Supervisory Board, Hansjoerg Plaggemars has no personal or business relationship with the company or its group companies, the company's governing bodies, or a shareholder holding a significant stake in the company that would require disclosure under C.13 of the German Corporate Governance Code.

**5.6 Mr. Tobias Reich, Member of the Executive Board of ConBrio Beteiligungen AG, Stuttgart, residing in Frankfurt am Main, is elected to the Supervisory Board effective as of the conclusion of the Annual General Meeting on June 10, 2026, and for the period until the end of the Annual General Meeting that decides on his discharge for the fiscal year ending December 31, 2030.**

Disclosures pursuant to Section 125(1) Sentence 5 of the German Stock Corporation Act (AktG):

Mr. Tobias Reich is currently not a member of any other statutory supervisory boards or comparable domestic or foreign supervisory bodies of commercial enterprises.

The corporate group under Wilhelm K. T. Zours—to whom, according to the most recent voting rights notification, 62.23% of the voting rights in Biofrontera AG are attributed—ly holds a 100% stake in ConBrio Beteiligungen AG, of which Mr. Tobias Reich is a member of the Management Board. Consequently, there is an (indirect) business relationship between Tobias Reich and a shareholder with a significant stake in the company.

Furthermore, in the opinion of the company's Supervisory Board, Tobias Reich has no personal or business relationship with the company or its group companies, the company's governing bodies, or a shareholder holding a significant stake in the company that would require disclosure under C.13 of the German Corporate Governance Code.

All six proposals take into account the Supervisory Board's objectives regarding its composition and competence profile. The Supervisory Board has verified that each of the proposed candidates is able to devote the time necessary to perform the duties of the office.

The résumés of all six proposed candidates are available on the company's website (<https://www.biofrontera.com/de/about-us/management-and-supervisory-board>) (each listing their most important activities in addition to their membership on the Supervisory Board of Biofrontera AG, as well as their knowledge, skills, and experience relevant to serving on the Supervisory Board of Biofrontera AG).

If the proposed candidates are elected, the Supervisory Board plans to re-elect Mr. Alexander Link as its Chairman and Dr. Helge Lubenow as its Vice Chairwoman.

## **6. Resolution on the approval of the compensation report pursuant to Section 162 of the German Stock Corporation Act (AktG)**

Pursuant to Section 162 of the German Stock Corporation Act (AktG), the Management Board and Supervisory Board of the listed company prepare an annual report on the remuneration granted and owed by the company and by companies within the same group (Section 290 of the German Commercial Code) to each current or former member of the Management Board and the Supervisory Board during the last fiscal year (Remuneration Report). The remuneration report for the 2025 fiscal year prepared by the Management Board and Supervisory Board was audited by the auditor in accordance with the requirements of Section 162(3) of the German Stock Corporation Act (AktG). The auditor's report is attached to the remuneration report. The Annual General Meeting of the listed company shall resolve on the approval of the audited remuneration report in accordance with Section 120a(4) of the German Stock Corporation Act (AktG).

The Supervisory Board and the Management Board propose that the following resolution be adopted:

*The remuneration report for the 2025 fiscal year, prepared and audited in accordance with Section 162 of the German Stock Corporation Act (AktG), which, together with the auditor's report on the audit of the remuneration report, is available on the company's website at <https://www.biofrontera.com/de/investoren/hauptversammlung> from the date of the notice of the meeting and throughout the Annual General Meeting, is hereby approved.*

## **II. Additional Information, Notes**

## **1. Total number of shares and voting rights at the time of convening the Annual General Meeting**

The total number of issued shares of the Company, each of which carries one voting right, amounts to 6,076,862 shares as of the date of the call for the Annual General Meeting (disclosure pursuant to Section 49 (1), Sentence 1, No. 1 of the Securities Trading Act).

No voting rights may be exercised from treasury shares held by the company. As of the date of convening the Annual General Meeting, the company holds no treasury shares.

This information refers to the date of publication of this notice in the Federal Gazette.

## **2. Requirements for Participation in the Annual General Meeting**

Only those shareholders who are entered in the share register and have registered in a timely manner are entitled to participate in the Annual General Meeting and to exercise their voting rights. The registration must be submitted to the company at the address

Biofrontera AG  
c/o GFEI HV GmbH  
Ostergrube 11  
30559 Hannover  
Email: hv@gfei.de

by no later than

June 3, 2026 (12:00 a.m.)

in writing (§ 126b BGB) in German or English.

Shares are not blocked by registration for the Annual General Meeting; shareholders may therefore continue to freely dispose of their shares even after registering for the Annual General Meeting. Requests for changes to the share register received by the Company after the end of the aforementioned registration deadline will only be processed and taken into account with effect from the day of the Annual General Meeting (registration freeze). The shareholding recorded in the share register as of the end of June 3, 2026 or Technical Record Date) is therefore decisive for the right to participate and vote.

## **3. Procedure for Voting by Proxy**

Shareholders who do not attend the Annual General Meeting may exercise their voting rights through a proxy, including, for example, an intermediary, a proxy advisor, or a shareholders'

association, by granting the appropriate power of attorney. In this case as well, timely registration and entry in the share register are required.

Proxies that are not granted in accordance with Section 135 of the German Stock Corporation Act (AktG) to an intermediary, a shareholders' association, a proxy advisor, or another person deemed equivalent under Section 135(8) of the German Stock Corporation Act (AktG) must be in writing (Section 126b of the German Civil Code (BGB)).

A proxy form, which may be used but is not required, will be sent to shareholders with the admission ticket and is available to shareholders at the website

<https://www.biofrontera.com/de/investoren/hauptversammlung>

If intermediaries or persons or associations deemed equivalent to them under Section 135(8) of the German Stock Corporation Act (AktG) (in particular shareholder associations and proxy advisors) are granted power of attorney, they must record the power of attorney in a verifiable manner (Section 135(1), sentence 2 of the German Stock Corporation Act (AktG)). We recommend that our shareholders coordinate with the aforementioned persons or associations regarding the form of the powers of attorney.

The granting of a proxy or its revocation vis-à-vis the Company, and proof of a proxy granted to a proxy holder or its revocation vis-à-vis the Company, must be in writing (Section 126b of the German Civil Code (BGB)) and may be submitted to the Company by 11:59 p.m. ( ) on June 9, 2026, to the following address:

Biofrontera AG  
c/o GFEI HV GmbH  
Ostergrube 11  
30559 Hanover  
Email: hv@gfei.de

On the day of the Annual General Meeting, the granting of a power of attorney, its revocation (if applicable), and proof of a power of attorney granted to a proxy or its revocation (if applicable) may be provided to the Company at the entrance and exit checkpoints for the Annual General Meeting.

If a shareholder authorizes more than one person, the Company may, pursuant to Section 134(3), second sentence, of the German Stock Corporation Act (AktG), reject one or more of them.

#### **4. Procedure for Voting by Proxy Representatives of the Company**

As an additional service, we offer our shareholders the option of being represented at the Annual General Meeting by proxies appointed by the company who are bound by instructions. In this case as well, timely registration and entry in the share register are required.

These proxies exercise voting rights exclusively in accordance with instructions if authorized and are not authorized to exercise voting rights without specific instructions from the

shareholder. Likewise, proxies appointed by the company do not accept instructions to file objections to General Meeting resolutions or to ask questions or submit motions.

A form for granting a proxy and issuing instructions to the proxy holder will be sent to shareholders with the admission ticket and is available to shareholders at the website

<https://www.biofrontera.com/de/investoren/hauptversammlung>

For organizational reasons, powers of attorney and instructions for the proxies appointed by the Company that are granted, amended, or revoked prior to the Annual General Meeting must be submitted in writing (§ 126b BGB) to the following address no later than June 9, 2026 , 12:00 a.m. (receipt decisive), :

Biofrontera AG  
c/o GFEI HV GmbH  
Ostergrube 11  
30559 Hanover  
Email: hv@gfei.de

On the day of the Annual General Meeting, shareholders may issue, amend, or revoke proxies and instructions to the proxies appointed by the company at the entrance and exit checkpoints until the start of voting.

#### **5. Requests to add items to the agenda pursuant to Section 122(2) of the German Stock Corporation Act (AktG)**

Shareholders whose shares together amount to one-twentieth of the share capital or the pro-rata amount of EUR 500,000.00 may request that items be placed on the agenda and announced. Each new item must be accompanied by a statement of reasons or a draft resolution.

The request must be submitted in writing or in the electronic form specified in Section 126a of the German Civil Code (BGB) (i.e., with a qualified electronic signature) to the Company's Management Board and must be received by the Company by the end of the day on May 10, 2026, at 12:00 a.m. ( ).

Please send such a request to the following address:

Biofrontera AG  
Board of Directors  
Hemmelrather Weg 201  
51377 Leverkusen  
Email (with a qualified electronic signature): ir@biofrontera.com

The proposers must prove that they have been holders of the shares for at least 90 days prior to the date of receipt of the request and that they will hold the shares until the Executive Board has decided on the proposal.

#### **6. Counter-motions and nominations by shareholders pursuant to Sections 126(1) and 127 of the German Stock Corporation Act (AktG)**

Counter-motions within the meaning of Section 126 of the German Stock Corporation Act (AktG), together with a statement of reasons, and nominations for election within the meaning of Section 127 of the German Stock Corporation Act (AktG), including the name of the shareholder and any statement by management, are available at the Internet address

<https://www.biofrontera.com/de/investoren/hauptversammlung>

if they are received by the company by midnight on May 26, 2026, at the address

Biofrontera AG  
Executive Board  
Hemmelrather Weg 201  
51377 Leverkusen  
Email: [ir@biofrontera.com](mailto:ir@biofrontera.com)

and the remaining requirements under Sections 126 and 127 of the German Stock Corporation Act (AktG) are met. Any statements from management will also be published at the aforementioned website. Counter-motions submitted by shareholders to any other address will not be considered.

#### **7. Shareholders' Right to Information at the Annual General Meeting (Section 131(1) of the German Stock Corporation Act (AktG))**

At the Annual General Meeting, any shareholder may, pursuant to Section 131(1) of the German Stock Corporation Act (AktG), request information from the Management Board regarding matters of the company, provided that such information is necessary for a proper assessment of the items on the agenda. The duty to provide information also extends to the company's legal and business relationships with affiliated companies and to the financial position of the Group and the companies included in the consolidated financial statements.

#### **8. Further explanations on the company's website**

Further explanations pursuant to Section 121(3), sentence 3, no. 3 of the German Stock Corporation Act (AktG) regarding the rights of shareholders under Sections 122(2), 126(1), 127, and 131(1) of the German Stock Corporation Act (AktG) are available online at

<https://www.biofrontera.com/de/investoren/hauptversammlung>.

## **9. Website where the information pursuant to Section 124a of the German Stock Corporation Act (AktG) is available**

The information pursuant to Section 124a of the German Stock Corporation Act (AktG) is made available to shareholders on the Internet on the Company's website at

<https://www.biofrontera.com/de/investoren/hauptversammlung>.

## **10. Information on data protection**

In connection with the conduct of the Annual General Meeting, the Company processes the following categories of personal data relating to shareholders, shareholder representatives, and guests: contact details (e.g., name or email address), information regarding the shares held by each individual shareholder (e.g., number of shares), and administrative data (e.g., admission ticket number). The processing of personal data in connection with the Annual General Meeting is based on Article 6(1)(c) of the General Data Protection Regulation (GDPR). According to this provision, the processing of personal data is lawful if the processing is necessary for compliance with a legal obligation. The Company is legally obligated to hold the Annual General Meeting of Shareholders. To fulfill this obligation, the processing of the aforementioned categories of personal data is essential. Without providing their personal data, the Company's shareholders cannot register for the Annual General Meeting.

The company is responsible for data processing. The contact details of the controller are:

Biofrontera AG  
Hemmelrather Weg 201  
51377 Leverkusen  
E-Mail: [datenschutz@biofrontera.com](mailto:datenschutz@biofrontera.com)

Personal data concerning the company's shareholders is generally not disclosed to third parties. In exceptional cases, third parties may also be granted access to this data if they have been commissioned by the company to provide services in connection with the conduct of the Annual General Meeting. These are typical AGM service providers, such as AGM agencies, attorneys, or auditors. Service providers receive personal data only to the extent necessary for the provision of the service.

Within the scope of the legally prescribed right of access to the list of participants at the Annual General Meeting, other participants and shareholders may view the data recorded about them in the list of participants. Furthermore, in the context of requests to amend the agenda, counter-motions, or counter-nomination proposals that are subject to disclosure requirements, their personal data will be published if such motions are submitted by shareholders or shareholder representatives.

Depending on the specific case, the above-mentioned data will be retained for up to three years (but not less than two years) after the conclusion of the Annual General Meeting and then deleted, unless further processing of the data is still necessary in the specific case

for the handling of motions, decisions, or legal proceedings relating to the Annual General Meeting.

Shareholders and shareholder representatives are entitled to the rights set forth in Articles 15–21 of the GDPR (the right of access to the personal data concerned, as well as the rights to rectification, erasure, restriction of processing, and the right to object to processing, and the right to data portability). With regard to the erasure of personal data, we refer to the statutory retention periods and Article 17(3) of the GDPR.

To exercise these rights, simply send an email to

[datenschutz@biofrontera.com](mailto:datenschutz@biofrontera.com)

In addition, shareholders and shareholder representatives also have the right to lodge a complaint with a data protection supervisory authority.

Shareholders and shareholder representatives may contact the company's data protection officer and at the following address:

Biofrontera AG  
Hemmelrather Weg 201  
51377 Leverkusen  
Email: [datenschutz@biofrontera.com](mailto:datenschutz@biofrontera.com)

Leverkusen, April 2026

The Executive Board